AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7781349
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (2 g IV) in moderate group
Trial: 2278325
Drug: Continuous interpleural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interpleural analgesia with 20 ml bupivacaine 0.5% with adrenaline 5 micrograms/ml
Trial: 2278325
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of interpleural bupivacaine and systemic morphine
Trial: 31702761
Drug: Cranberry +health™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry +health™ cranberry supplement (cranberry chew)
Trial: 29090491
Drug: MRI Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI Group (MG) - Accent MRI™ conditional pacing system, n = 140
Trial: 26044566
Drug: cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cilostazol 200 mg/day
Trial: 21692286
Drug: Meridian‐collateral electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meridian‐collateral electric information therapy combined with pricking and cupping
Trial: 21692286
Drug: Acyclovir administered
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir administered orally
Trial: 19747869
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintained usual daily activity
Trial: 14750569
Drug: Intracameral or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral or intravitreal injection of 0.1 mL antibiotic (40 microg gentamicin and 45 microg clindamycin)
Trial: 14750569
Drug: Balanced saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced saline solution (BSS) injection
Trial: 9662313
Drug: Daily placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placement of prostaglandin gel
Trial: 9662313
Drug: Daily membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily membrane stripping
Trial: 9662313
Drug: Daily cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cervical examinations
Trial: 10208998
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg/d) and colestipol (30 g/d)
Trial: 10208998
Drug: Niacin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (4 g/d) and colestipol
Trial: 10208998
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with placebo alone or with colestipol
Trial: 2142911
Drug: Picotamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (600 mg daily for six months)
Trial: 24374394
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic solution (LAS) applied to the columella (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Trial: 24374394
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic solution (LAS) applied to the nasal dorsum (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Trial: 24374394
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic solution (LAS) applied to the nasal dorsum followed by LAS to the columella after 10 minutes (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Trial: 17086465
Drug: 4:00 PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4:00 PM inhalation of 4.5% saline
Trial: 17086465
Drug: 4:00 AM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4:00 AM inhalation of 4.5% saline
Trial: 15583260
Drug: Safe storage
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safe storage of medicines
Trial: 11704585
Drug: Turbuhaler (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (0.25 mg terbutaline)
Trial: 11704585
Drug: Turbuhaler (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (0.5 mg terbutaline)
Trial: 11704585
Drug: pMDI (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pMDI (0.25 mg terbutaline)
Trial: 11704585
Drug: pMDI (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pMDI (0.5 mg terbutaline)
Trial: 2917596
Drug: 5-Methoxypsoralen (5-MOP)
RxNorm normalized name: 5 methoxypsoralen
DrugBank: Bergapten (DB12216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Methoxypsoralen (5-MOP) 40 mg/day
Trial: 31696603
Drug: Mid-dose (PHEN/TPM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose (PHEN/TPM 7.5 mg/46 mg)
Trial: 31696603
Drug: Top-dose (PHEN/TPM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top-dose (PHEN/TPM 15 mg/92 mg)
Trial: 31696603
Drug: Mid-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose
Trial: 31696603
Drug: Top-dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top-dose
Trial: 18379058
Drug: Patch adhesion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch adhesion
Trial: 16441467
Drug: 1-week triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week triple therapy for eradication of H. pylori
Trial: 16441467
Drug: Crossover open-label
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover open-label triple therapy
Trial: 12969090
Drug: HM-CAP (immunoglobulin-G)
RxNorm normalized name: DEXTRAN HM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM-CAP (immunoglobulin-G)
Trial: 12969090
Drug: Pyloriset EIA-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyloriset EIA-G
Trial: 10710743
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist leuprolide acetate, 3.75 mg intramuscularly every 28 days
Trial: 3903644
Drug: Metoclopramide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (1 mg/kg, intravenous)
Trial: 3903644
Drug: Bethanechol (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (0.075 mg/kg, subcutaneous)
Trial: 29066028
Drug: Group B2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B2: 80 kVp, 30 ml of iohexol at 4.5 ml/s; hybrid iterative reconstruction (HIR) and IMR.
Trial: 29066028
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 120 kVp, 50 ml of iopromide at a flow rate of 5 ml/s; filtered back projection (FBP) reconstruction.
Trial: 24041792
Drug: ITX5061 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITX5061 150 mg/day for 28 days (C150)
Trial: 24041792
Drug: ITX5061 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITX5061 150 mg/day for 3 days (A150)
Trial: 24041792
Drug: ITX5061 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITX5061 150 mg/day for 14 days (B150)
Trial: 22705785
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus strain L-55-contained yogurt
Trial: 19558057
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU of intravenous heparin during surgery
Trial: 12399203
Drug: H-B-VAXII (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, and 6 months (Schedule A)
Trial: 12399203
Drug: H-B-VAXII (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, 2, and 12 months (Schedule B)
Trial: 1775523
Drug: Prazepam (30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazepam (30‐60 mg)
Trial: 1775523
Drug: Clomipramine (75‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (75‐150 mg)
Trial: 31804659
Drug: Standard multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multimodal treatment
Trial: 27595142
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg intravenous infusion given over 2 h at baseline, and again at 2 weeks and 6 weeks after the first infusion)
Trial: 27595142
Drug: Ciclosporin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (2 mg/kg per day by continuous infusion for up to 7 days, followed by twice-daily tablets delivering 5.5 mg/kg per day for 12 weeks)
Trial: 17301634
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with endurance training (ET)
Trial: 17301634
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) without endurance training (ET)
Trial: 9879918
Drug: Intensive fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive fluoride mouthrinsing (10 ml of 0.045% NaF neutral solution once a day for 3 days, twice a year, totaling 6 rinses per year)
Trial: 2525449
Drug: Clinofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinofibrate (200 mg, three times daily for 16 weeks)
Trial: 2525449
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 mg, three times daily for 16 weeks)
Trial: 29753264
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg dexamethasone)
Trial: 25795409
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus gemcitabine (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Trial: 25795409
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus gemcitabine (paclitaxel 175 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Trial: 20649689
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/d with or without medroxyprogesterone acetate (MPA, 10 mg/d)
Trial: 20649689
Drug: CEE alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE alone therapy
Trial: 15363253
Drug: Portal vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein chemotherapy (5‐fluorouracil infusion at 1g per day for 7 days after operation)
Trial: 15363253
Drug: Intraluminal chemotherapy
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal chemotherapy (5‐fluorouracil 0.5 g injected during operation)
Trial: 11215556
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (Group 1)
Trial: 9024252
Drug: Recombinant GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant GH treatment for 9 months (adjusted for body surface area) in men
Trial: 9024252
Drug: Recombinant GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant GH treatment for 9 months (adjusted for body surface area) in women
Trial: 9024252
Drug: Recombinant GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant GH treatment for 9 months in men
Trial: 8274360
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (366 mg Mg2+/d)
Trial: 3095501
Drug: Chex‐UP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chex‐UP chemotherapy (four-drug combination: cyclophosphamide, hexamethylmelamine, 5‐fluorouracil, and cisplatin)
Trial: 3095501
Drug: Chex‐UP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chex‐UP chemotherapy
Trial: 15890758
Drug: Moderate doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate doses of training (3-6 months)
Trial: 15890758
Drug: Heavy doses
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy doses of training (12 months)
Trial: 8798349
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Daflon 500 mg with LMWH (Group B: n = 595)
Trial: 8798349
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Daflon 500 mg with LMWH (Group D: n = 93)
Trial: 29663871
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (15 mg for men; 12 mg for women)
Trial: 27906432
Drug: Concurrent radio
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent radio chemotherapy and intensity modulated radiotherapy
Trial: 27906432
Drug: Concurrent radio
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent radio chemotherapy and hypofractionation (DT of 42.56 Gy, 2.66Gy/fraction, 16 times, during 22-24 days)
Trial: 23910578
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment with FEIBA NF
Trial: 20493549
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 mg, 4 mg, or 8 mg once daily)
Trial: 15832627
Drug: Deeper processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deeper processing during encoding (semantic, phonemic, or graphemic questions) for twice-presented items
Trial: 2505712
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg orally
Trial: 2505712
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg orally
Trial: 2505712
Drug: Perindopril 8
RxNorm normalized name: perindopril 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 8 mg orally
Trial: 25774559
Drug: Compliance Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance Therapy (up to six weekly sessions)
Trial: 19081418
Drug: ABT-335 +
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 + simvastatin 20 mg
Trial: 19081418
Drug: ABT-335 +
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 + simvastatin 40 mg
Trial: 19081418
Drug: ABT-335 monotherapy
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 monotherapy (135 mg)
Trial: 8942424
Drug: 3,4-didehydroretinyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-didehydroretinyl acetate (DRA) administered at standard doses: 5.3 mumol for children < 6 y, 7.0 mumol for children 6-12 y, 8.8 mumol for adults and children > 12 y.
Trial: 8942424
Drug: DRA in
RxNorm normalized name: EPHEDRA INTERMEDIA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRA in vitamin E-containing corn oil, with or without 4.6 mmol all-rac-alpha-tocopheryl acetate/L.
Trial: 1848053
Drug: Towne live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Towne live attenuated virus vaccine
Trial: 6220334
Drug: Almitrine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (60 mg/24 h)
Trial: 6220334
Drug: Raubasine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raubasine (20 mg/24 h)
Trial: 29324776
Drug: Control (direct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (direct infertility treatment)
Trial: 26528775
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg + placebo
Trial: 24656590
Drug: Intratendinous injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRATENDINOUS LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratendinous injection of platelet-rich plasma (PRP) under ultrasound (US) guidance
Trial: 11870792
Drug: Long pulsed
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long pulsed Nd:YAG laser treatment (1-5 sessions)
Trial: 11870792
Drug: Long pulsed
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long pulsed Nd:YAG laser treatment (5 sessions)
Trial: 11870792
Drug: Long pulsed
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long pulsed Nd:YAG laser treatment
Trial: 2134116
Drug: Oxiracetam (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam (800 mg t.i.d.)
Trial: 30368018
Drug: Fulranumab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab (9 mg)
Trial: 24804272
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion protocol (transfusion if hemoglobin dropped below 9.9 g dL(-1))
Trial: 24804272
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion protocol (transfusion if hemoglobin dropped below 7.7 g dL(-1))
Trial: 30049303
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of Mirogabalin 15 mg with Metformin 850 mg
Trial: 11995260
Drug: Montelukast (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5-10 mg once daily for three months)
Trial: 10784382
Drug: Chronic supplementation
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic supplementation with 15 g of arginine aspartate daily for 14 days
Trial: 7568859
Drug: Uniphasic injection
RxNorm normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphasic injection of 38 g of iodine
Trial: 7568859
Drug: Uniphasic injection
RxNorm normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphasic injection of 26 g of iodine
Trial: 7568859
Drug: Biphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic injection
Trial: 2122131
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with mitomycin C (MMC), tegafur, and PSK
Trial: 7427705
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg four times daily for seven days
Trial: 7427705
Drug: Tetracycline 500
RxNorm normalized name: oxytetracycline 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 500 mg four times daily for seven days
Trial: 7427705
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (250 mg and 500 mg)
Trial: 31647886
Drug: Supplemental whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental whey protein (PRO) 25 g, 3×/day for 12 weeks
Trial: 31647886
Drug: Isocaloric placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric placebo (PLA) 25 g, 3×/day for 12 weeks
Trial: 30069754
Drug: Mental health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental health conditions (e.g., schizophrenia, obsessive compulsive disorder)
Trial: 17609405
Drug: Proinsulin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinsulin levels >5 pmol/l with blood glucose levels <2.5 mmol/l during a 72 h fast test
Trial: 17609405
Drug: C-peptide levels
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide levels >0.2 nmol/l
Trial: 17609405
Drug: Proinsulin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinsulin levels >22 pmol/l
Trial: 17609405
Drug: Proinsulin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinsulin levels <22 pmol/l
Trial: 15308521
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral azithromycin for 13 weeks (1 g single dose for Chlamydia infection)
Trial: 11355895
Drug: rEpo administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rEpo administration (30 IU/kg)
Trial: 11355895
Drug: rEpo administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rEpo administration (various treatments)
Trial: 11355895
Drug: Multiparametric formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiparametric formula including hematocrit value, reticulocyte count, soluble transferrin receptor content, and beta-globin mRNA concentration
Trial: 27809891
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate 1200 mg/day